A 12-week Field Trial of the Move Physical Activity Support Program

Inclusion Criteria: For both participant partners and the provider partner: * Have access to a computer and/or smart phone, and Wi-Fi * Speak English For the participant partners only: * Body Mass Index 25-45 kg/m2 * Insufficiently active (defined as \<150 min/week of voluntary exercise at moderate intensity over the past 3 months) * Willing not to enroll in any other formal weight loss, physical activity program, or fitness center membership over the next 5 months. * Have a primary care physician (or has access to a healthcare professional and/or are willing to establish care with a primary care physician prior to study enrollment) to address medical issues which may arise during screening or study procedures/interventions. * Capable and willing to give informed consent, understand exclusion criteria, attend the Move+ program sessions, and complete outcome measures. For the provider partners only: * \>1 year experience with delivering lifestyle interventions involving changes in diet and/or exercise behaviors. Exclusion Criteria: For participant partners: * Considered high risk, based on the American College of Sports Medicine Guidelines for Exercise Testing and Prescription60 (i.e. have CVD symptoms or known CVD, diabetes, or end-stage renal disease). * Females who are currently pregnant or lactating, were pregnant within the past 3 months, or planning to become pregnant in the next 5 months will also be excluded * Self-reported cardiovascular disease: * Cardiac, peripheral vascular, or cerebrovascular disease * Self-reported symptoms suggestive of cardiovascular disease: * pain, discomfort in the chest, neck, jaw, arms, or other areas that may result from cardiac ischemia; shortness of breath at rest or with mild exertion; dizziness or syncope; orthopnea or paroxysmal nocturnal dyspnea; ankle edema; palpitations or tachycardia; intermittent claudication. * Self-reported end-stage renal disease * Self-reported diabetes (history of type 1 or type 2 diabetes) * Uncontrolled hypertension, defined as diastolic blood pressure \>100 mmHG, systolic blood pressure \>160 mmHG, or resting heart rate \>100 bpm as measured in duplicate at the screening visit after 5 minutes of rest in a seated position. * Self-reported pulmonary disease requiring chronic oxygen supplementation; severe asthma or chronic obstructive pulmonary disease requiring hospitalization in past year. * Plans to relocate in the next 4 months * Currently participating in or planning to participate in any formal weight loss, dietary modification, or physical activity/exercise programs or clinical trials. * Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. Score \> 18 on BDI will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study. * History of other significant psychiatric illness (e.g., psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to the exercise intervention. * History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder. Score \>20 on the EATS-26 or pattern of response on the QEWP-5 suggestive of possible binge eating disorder or bulimia will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study. * Current alcohol or substance abuse * Nicotine use (current or past 6 months) * Regular use of prescription or over-the-counter medications known to significantly impact appetite, weight, sleep, or energy metabolism (e.g., appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants) * Regular use of obesity pharmacotherapeutic agents within the last 6 months. * Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed \> 1 year before screening, (2) lap banding if the band has been removed \> 1 year before screening, (3) intragastric balloon if the balloon has been removed \> 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed \> 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed \> 1 year before screening. For provider partners: * None